This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Granulomas  • Nail Diseases  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Geftinib (Iressa; AstraZeneca Pharmaceuticals LP, Wilmington, Del) is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor used to treat non–small cell lung cancer (NSCLC). Recently, this agent has been a point of controversy. In patients who demonstrate a response, the results are often dramatic; however, such a response has occurred in as few as 10% of treated patients.¹

In June 2005, using data from a phase 3 trial that failed to demonstrate prolonged survival, the US Food and Drug Administration revised the labeling to indicate continued use only in those with a prior response to gefitinib or in further clinical trials.² Similar related monoclonal antibodies include cetuximab, panitumumab, or erlotinib. Despite recognized cutaneous manifestations attributed to this entire class of EGFR inhibitors, there is a paucity of discussion regarding such events within the major American dermatology journals.

Report of a Case

A 78-year-old woman with NSCLC presented to our clinic with the complaint . . . [Full Text of this Article]

Comment

AUTHOR INFORMATION
Whitney A. High, MD